Alcon (ALC) said late Wednesday it has acquired a majority stake in Aurion Biotech, a company developing cell therapies to treat eye diseases.
Financial details weren't provided.
Aurion will operate as a separate company to advance its cell therapy asset AURN001 into phase 3 to treat corneal edema secondary to corneal endothelial disease during H2, Alcon said.
Aurion has received breakthrough therapy designation from the US Food and Drug Administration for AURN001, Alcon said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.